New obesity drug candidate enters first human safety tests

NCT ID NCT07654972

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage study tests an experimental drug called LY4174794 in 108 healthy volunteers who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it, not to measure weight loss. Participants will receive either the drug or a placebo and be monitored for about 7 to 11 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4174794 (an experimental drug)
What this could lead to: If successful, this could lead to a new medication for weight management in people with obesity or overweight.
What could go wrong: This is a very early Phase 1 trial with only 108 participants, focused on safety, not weight loss. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

ICON Early Phase Services, LLC
RECRUITING

San Antonio, Texas, 78232, United States
ICON Early Phase Services, LLC
NOT_YET_RECRUITING

Salt Lake City, Utah, 84124, United States
Lilly Centre for Clinical Pharmacology
NOT_YET_RECRUITING

Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.